The instrument Medtronic's surgical robot was missing is the one surgeons use every day. On September 16, the FDA cleared the LigaSure RAS Maryland instrument for use with the Hugo robotic-assisted surgery system, the first time LigaSure vessel sealing has been cleared for robotic surgery in the United States. The device seals and cuts vessels, thick tissue and lymphatics up to 7 millimeters, in about two seconds, paired exclusively with the Valleylab FT10 energy platform.

The clearance fills a hole that has defined Hugo's American launch. The robot arrived in the United States cleared for urology in December 2025, but without an integrated energy instrument. Surgeons doing the cutting-and-sealing work of a prostatectomy or nephrectomy had to fall back on laparoscopic assistance, a workaround that undercut the point of a robot. LigaSure, the incumbent laparoscopic sealer Medtronic acquired with Covidien in 2015, is the instrument tens of thousands of surgeons were already trained on. Giving it to Hugo removes a switching objection, in the words of Medtronic's surgical chief medical officer, Matthew Kroh, who said surgeons can now carry "the confidence and control they already rely on into their robotic-assisted cases."

The label still sets the ceiling

The catch is in the fine print, and it is a real one. The instrument clearance does not expand what Hugo is allowed to do in the United States. Hugo's U.S. label remains urologic procedures only, about 230,000 surgeries a year across prostatectomy, nephrectomy and cystectomy. The 510(k) filings that would open the robot to general and gynecologic surgery, submitted in June, are still pending. In Europe, where Hugo has carried the CE mark since 2021 and LigaSure joined it in 2025, the same instrument works across more than 50 procedure types in urology, general surgery and gynecology. In the United States, the near-term revenue ceiling is set by the indication label, not by the instrument count, and analysts have been explicit that the clearance is incremental rather than transformational.

That framing matters because of how robotic surgery economics actually work. The systems are the gateway; the consumables are the business. Intuitive Surgical derives roughly three-quarters of its revenue from instruments, accessories and service rather than from selling da Vinci units, and a cleared energy instrument attached to a placed Hugo is exactly that recurring layer. Medtronic has said it expected roughly 250 installed Hugo units worldwide by the end of its fiscal year, with procedure volume growing two to three times the market rate, but it has not disclosed its U.S. installed base, procedure volumes or pricing.

The competitive frame is getting crowded

Hugo's problem has never been the absence of a good instrument. It is that the incumbent owns the ecosystem. Intuitive had 11,395 da Vinci systems installed worldwide as of June 2026, ran 2.4 million procedures last year, and its da Vinci 5 collects the procedure data that hospital systems are starting to buy. Medtronic did not say whether the LigaSure instrument feeds usage data into its Touch Surgery platform, a gap against the data-rich incumbent. Early Hugo adopters have also reported real friction: arm-cart docking times around 20 minutes against about 12.5 for the da Vinci Xi, a setup learning curve that one published early-adopter analysis warned could slow uptake, and at least one minor bedside-assistant injury from a moving arm cart.

And now there is a third entrant. Johnson & Johnson won FDA De Novo authorization for its Ottava table-integrated system in July, entering with ten general surgery procedures and a smaller floor footprint. Medtronic's own moves have muddied its message: a $700 million investment in China's Cornerstone Robotics this spring led some investors to read a reduced commitment to Hugo, a reading chief executive Geoff Martha rejected outright. "We are doubling down here," he told investors, framing Cornerstone's Sentire system as a non-U.S. play while Hugo remains the American platform.

What the clearance changes, and what it does not

The honest read is that September 16 was a milestone, not a breakout. Hugo now has its standard working instrument in the U.S. market, which was the largest visible gap in the pitch Medtronic has been making since the first American case at Cleveland Clinic in February. The urology-only ceiling, the pending general and gynecologic filings, and the undisclosed installed base remain the variables that will decide whether the robot becomes a real competitor to da Vinci or a niche urology offering with a familiar instrument attached. Medtronic's fiscal year ends in April, so even a successful launch cycle lands its revenue in fiscal 2027, and the company's own framing has kept expectations modest. The instrument was the missing piece. The market is still the missing proof.

Primary sources

  1. Medtronic newsroom, September 16, 2026 release, for the LigaSure RAS Maryland clearance, device specifications, and Dr. Kroh's statement.
  2. Medtronic newsroom, December 3, 2025 release, for Hugo's urology-only U.S. clearance and the Expand URO study basis.
  3. Medtronic newsroom, June 3, 2026 release, for the pending general and gynecologic 510(k) filings and the Embrace Gynecology IDE.
  4. MD+DI, coverage of the Cornerstone Robotics investment, for Martha's "doubling down" quote and the Hugo placement commentary.